逍遥丸治疗轻中度抑郁的疗效与安全性:随机对照试验研究方案
本研究为多中心、双盲、随机安慰剂对照临床试验,共纳入108例轻中度抑郁(肝郁脾虚证)患者,分为逍遥丸组(每日两次,连用4周)、安慰剂组(每日两次,连用4周)和不服药正常组,以汉密尔顿抑郁量表(HAMD)和中医证候量表为主要及次要结局,评估逍遥丸的疗效与安全性。
要点
- 逍遥丸组每日两次服用逍遥丸,连用4周,安慰剂组每日两次服用安慰剂,连用4周。
- 主要和次要结局分别为汉密尔顿抑郁量表(HAMD)和中医证候量表。
- 评估时间点为基线、首次治疗后1周、2周和4周,并在基线和4周进行探索性结局评估。
核心结论
- 本研究结果将为逍遥丸治疗轻中度抑郁伴肝郁脾虚证患者的疗效和安全性提供临床证据。
研究设计与样本
- 多中心、双盲、随机安慰剂对照临床试验,共纳入108例受试者,分为逍遥丸组、安慰剂组和正常组三组。
主要发现
- 逍遥丸组每日两次服用逍遥丸,连用4周;安慰剂组每日两次服用安慰剂,连用4周;正常组不服用任何药物。
- 主要和次要结局分别为汉密尔顿抑郁量表(HAMD)和中医证候量表,评估时间点为基线、首次治疗后1周、2周和4周。
- 探索性结局在基线和4周时评估,以探索逍遥丸的作用机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Depression is one of the most frequent and severe psychiatric conditions. Many chemical drugs to treat depression are associated with adverse reactions and have shortcomings. Traditional Chinese medicine is of great significance in the prevention and treatment of depression. Xiaoyao pills has achieved good results in clinical application, which has the advantages of quick effect and no obvious adverse reactions. The aim of our study is to evaluate the efficacy and safety of Xiaoyao pills on mild to moderate depression patients. METHODS: This study is a multi-centre, double-blinded, randomized and placebo-controlled clinical trial. A total of 108 participants are assigned to three groups: Xiaoyao pill group taking Xiaoyao pills twice daily for 4 weeks, placebo group taking placebos twice daily for 4 weeks and normal group without taking any drug. The primary and secondary outcome measures are the Hamilton Depression Scale (HAMD) and Traditional Chinese Medicine (TCM) Syndrome Scale. The assessment is at baseline (before treatment initiation), 1 week, 2 weeks 4 weeks after the first treatment. Exploratory outcome is also assessed to explore the mechanism of Xiaoyao pills at baseline and 4 weeks. DISCUSSION: The results from this study will provide clinical evidence on the efficacy and safety of Xiaoyao pills in patients with mild to moderate depression with syndrome of liver stagnation and spleen deficiency. TRIAL REGISTRATION: ClinicalTrials.gov ISRCTN12746343. Registered on September 25, 2020.
引用
- Xue Z, Huang Z, Cheng SL, et al. Efficacy and safety of Xiaoyao pills for mild to moderate depression: study protocol for a randomized controlled trial. Trials. 2022. PMID: 34983620. doi:10.1186/s13063-021-05909-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。